Shan-ney Huang

Biography

Shan-Ney Huang  is the chairman of  oneness biotech.We discover and innovate to satisfy unmet medical needs at Oneness. We strive to set new standards in health care. Our current new drug candidates in the pipeline include: ●ON101- New drug for diabetic foot ulcer healing  The results of the interim analysis of the primary endpoint of the ON101 Phase III clinical trial of chronic diabetic foot ulcers had reached a statistically significant difference. Upon completion of the phase III interim analysis, the company will apply for Expedited programs to the TFDA in Taiwan to accelerate the listing of new drugs to meet the unmet medical needs. ●OB318- New drug for anti-liver cancer Approved by the US Food and Drug Administration to implement Phase I clinical trials are ready to start.

Research Interest

Cancer